ArticleJournal of thoracic disease2025
Pathogen distribution and prognostic risk factors in respiratory intensive care unit (RICU) patients of a large general hospital before and after COVID-19 pandemic.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Drug-resistant tuberculosis and pulmonary co-infections in immunocompromised patients: from multi-omics to precision therapy.Frontiers in microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The evolving pathogen spectrum and prognosis of severe pulmonary infections in the respiratory intensive care unit (RICU) during the coronavirus disease 2019 (COVID-19) pandemic remain unclear. This study aimed to investigate shifts in the pathogen landscape of pulmonary infections among intensive care unit (ICU) patients following the regular prevention and control of COVID-19. Methods: A total of 132 patients with pulmonary infections admitted to the RICU of the First Affiliated Hospital of Anhui Medical University between January 2022 and March 2023 were included in the study. Patients were categorized into two cohorts: pre-strategy (n=65, Jan to Nov 2022) and post-strategy (n=67, Dec 2022 to Mar 2023), based on the implementation of regular COVID-19 prevention and control measures. Metagenomic next-generation sequencing (mNGS), and conventional tests using bronchoalveolar lavage fluid (BALF) and blood samples were used to detect pathogens. Retrospective data were obtained from the patients' medical records. The spectrum of pathogens was analyzed. Additionally, univariate and multivariate logistic regression models were employed to analyze the risk factors associated with adverse outcomes. Results: After the regular prevention and control of COVID-19 in December 2022, there was a significant shift in the pathogen landscape. The proportion of patients with severe acute respiratory coronavirus 2 (SARS-CoV-2) increased dramatically from 0% to 74.6%. This was accompanied by a significant rise in the incidence of Conclusions: Our findings highlight the pathogen spectrum in RICU patients changed significantly after the shift in COVID-19 policy. Co-infections with fungi and G+ bacteria require increased clinical vigilance and early intervention to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.